PSDV (Mcap $29 M) 3x Approved Drugs // 1x in Phase 3 // US NDA filing in January = 10 BAGGER EASILY
THIS LOW FLOAT ROCKET IS DEFINITELY THE CHEAPEST BIOTECH OUT THERE ..PLEASE DO YOUR OWN DD FOLKS..
This undiscovered low float Stock will hit $7++ before FDA approval in 1H 2013 .PSDV will move into double digits easily with FDA approval for Blockbuster candidate Iluven for DME .There is NO FDA approved drugs for DME (Diabetic Macular Edema) a Blockbuster Market . Iluven is approved in Europe and Market launch will start during 2013
Upon US approval of ILUVIEN, pSivida would be entitled to receive a $25 million milestone payment from Alimera and 20 percent of net profits, as defined, on sales of the drug by Alimera.
DME is a potentially blinding disease that affects over one million people in the United States. Currently there are no FDA approved drugs for the treatment of DME.The U.S. market for DME is $1.5 billion to $4 billion.
Market Cap: $29.5 M
Cash: $17.65 M
Shares Out: 23.3
Our proven proprietary technologies enable us to achieve highly focused, long-term delivery of therapeutics. We have developed three of the only four products approved by either the US or EU for the long-term, sustained-released delivery of drug to treat chronic eye disease.
Our most recently approved product, ILUVIEN® for diabetic macular edema (DME), has received marketing authorization in the UK, Austria, France, Germany and Portugal, with approvals in Italy and Spain anticipated in the coming months. These marketing authorizations followed a positive outcome of the European Decentralized Procedure involving these seven countries. ILUVIEN, licensed to Alimera Sciences, Inc. (Alimera), is approved for use in the treatment of vision imparement associated with chronic DME considered insufficiently responsive to available therapies.